Triveni Bio closed a $65 million Series C to advance TRIV-573, its bispecific candidate for atopic dermatitis. The company said proceeds will fund clinical development tied to its eczema program, aiming to move the therapy through key early evaluation steps. For eczema investors, the round underscores ongoing emphasis on targeted immunology and multi-specific approaches that attempt to improve both efficacy breadth and durability. It also signals competitive financing conditions in inflammatory disease drug development. The financing structure indicates Triveni is scaling resources to accelerate data generation needed for later-phase decision points, including dose selection and biomarker strategy.